CL2019000273A1 - Composición mejorada de teneligliptina y metformina y proceso para prepararla. - Google Patents
Composición mejorada de teneligliptina y metformina y proceso para prepararla.Info
- Publication number
- CL2019000273A1 CL2019000273A1 CL2019000273A CL2019000273A CL2019000273A1 CL 2019000273 A1 CL2019000273 A1 CL 2019000273A1 CL 2019000273 A CL2019000273 A CL 2019000273A CL 2019000273 A CL2019000273 A CL 2019000273A CL 2019000273 A1 CL2019000273 A1 CL 2019000273A1
- Authority
- CL
- Chile
- Prior art keywords
- metformin
- distribution
- improved
- active
- excipients
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003105 metformin Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical group O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 title 1
- 229950000034 teneligliptin Drugs 0.000 title 1
- 238000009792 diffusion process Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016010682A MX384961B (es) | 2016-08-17 | 2016-08-17 | Composición mejorada de teneligliptina y metformina y proceso para prepararla. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000273A1 true CL2019000273A1 (es) | 2019-06-28 |
Family
ID=61196457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000273A CL2019000273A1 (es) | 2016-08-17 | 2019-02-01 | Composición mejorada de teneligliptina y metformina y proceso para prepararla. |
Country Status (8)
| Country | Link |
|---|---|
| AR (1) | AR109253A1 (fr) |
| CL (1) | CL2019000273A1 (fr) |
| CO (1) | CO2019001110A2 (fr) |
| DO (1) | DOP2019000035A (fr) |
| EC (2) | ECSP19010066A (fr) |
| MX (1) | MX384961B (fr) |
| PE (1) | PE20190402A1 (fr) |
| WO (1) | WO2018033808A1 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014080383A1 (fr) * | 2012-11-26 | 2014-05-30 | Ranbaxy Laboratories Limited | Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques |
| WO2015132679A1 (fr) * | 2014-03-05 | 2015-09-11 | Glenmark Pharmaceuticals Ltd | Compositions de ténéligliptine |
-
2016
- 2016-08-17 MX MX2016010682A patent/MX384961B/es unknown
-
2017
- 2017-06-23 PE PE2019000305A patent/PE20190402A1/es unknown
- 2017-06-23 WO PCT/IB2017/053749 patent/WO2018033808A1/fr not_active Ceased
- 2017-07-04 AR ARP170101849A patent/AR109253A1/es not_active Application Discontinuation
-
2019
- 2019-02-01 CL CL2019000273A patent/CL2019000273A1/es unknown
- 2019-02-05 CO CONC2019/0001110A patent/CO2019001110A2/es unknown
- 2019-02-12 EC ECSENADI201910066A patent/ECSP19010066A/es unknown
- 2019-02-18 DO DO2019000035A patent/DOP2019000035A/es unknown
- 2019-06-25 EC ECSENADI201944926A patent/ECSP19044926A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019002909A2 (pt) | 2019-05-21 |
| AR109253A1 (es) | 2018-11-14 |
| DOP2019000035A (es) | 2019-06-30 |
| MX384961B (es) | 2025-03-14 |
| CO2019001110A2 (es) | 2019-04-12 |
| MX2016010682A (es) | 2018-02-16 |
| PE20190402A1 (es) | 2019-03-13 |
| ECSP19044926A (es) | 2019-07-31 |
| WO2018033808A1 (fr) | 2018-02-22 |
| ECSP19010066A (es) | 2019-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR134152A2 (es) | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| CO2020002647A2 (es) | Composiciones de glp-1 y sus usos | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| UY37168A (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| CL2019000571A1 (es) | Formulaciones de carbamato de (r) -2-amino-3-fenilpropilo. | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2016011038A (es) | Compuestos para el tratamiento de trastornos mediados por complemento. | |
| MX392572B (es) | Compuestos del péptido yy (pyy) selectivos y sus usos. | |
| MX373318B (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer. | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| ECSP17085669A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| PE20200746A1 (es) | AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO | |
| MX2017004440A (es) | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX2022002667A (es) | Composicion oftalmica para el tratamiento de uveitis. | |
| CO2021014755A2 (es) | Compuestos inhibidores de la masp y usos de estos | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| CL2019000273A1 (es) | Composición mejorada de teneligliptina y metformina y proceso para prepararla. | |
| EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением |